Pasireotide
پاسیرئوتید
🧬 Systemic Hormonal Preparations, Excl. Sex Hormones And InsulinsSomatostatin analogue
Market / country: 🇺🇸 USA
Signifor (US)
🧮 Dose calculator
Cushing disease · Regimen source: FDA Signifor · 2.1
- • Range 0.3–0.9 mg twice daily; titrate by urinary free cortisol. Before starting: FPG, HbA1c, liver tests, ECG, gallbladder ultrasound, potassium and magnesium. Child-Pugh B: start 0.3, max 0.6 mg twice daily; avoid in Child-Pugh C. FDA Signifor · 2.1FDA Signifor · 2.2FDA Signifor · 2.3
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Warnings
- • Hypocortisolism; hyperglycaemia and diabetes (common); bradycardia and QT prolongation; liver test elevations; cholelithiasis; deficiency of other pituitary hormones. FDA Signifor · 5
Formulations
- 0.3 mg/mL ampule — injection 🇺🇸 USA FDA Signifor · 3
- 0.6 mg/mL ampule — injection 🇺🇸 USA FDA Signifor · 3
- 0.9 mg/mL ampule — injection 🇺🇸 USA FDA Signifor · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Signifor · 8.1
“Risk Summary The limited data with SIGNIFOR in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Signifor · 8.2
“Risk Summary There is no information available on the presence of SIGNIFOR in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Signifor · 8.4
“Safety and effectiveness of SIGNIFOR have not been established in pediatric patients.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Signifor · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)] .”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Signifor · 8.3
“… zation of serum cortisol levels in female patients with Cushing's disease treated with pasireotide may lead to improved fertility.”
🔗 Reference links
- FDA (approval record)NDA200677
- DailyMed (FDA label)FDA Signifor
- MedlinePlus (NIH)Pasireotide Injection
- WHO ATC/DDDH01CB05
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Signifor · 3FDA Signifor · 2.1FDA Signifor · 2.2FDA Signifor · 2.3FDA Signifor · 5FDA Signifor · SPL approval / marketing categoryFDA Signifor · 8.1FDA Signifor · 8.2FDA Signifor · 8.4FDA Signifor · 8.5FDA Signifor · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified